Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Entelos signs Unilever for “virtual patient”
The computer model of human physiology structures data in a way that enables identification of the key factors associated with the development of skin sensitization. Entelos claims the
The computer model of human physiology structures data in a way that enables identification of the key factors associated with the development of skin sensitization. Entelos claims the
The analysis was conducted by an independent data safety monitoring board (DSMB). In addition to its recommendation that the trial continue, the DSMB supported the use of endoscopic
The license agreement will specifically be aimed at the development and commercialization of OSI’s dipeptidyl peptidase IV (DPIV) inhibitors for the treatment of type 2 diabetes. OSI will
Two phase III clinical trials were conducted to evaluate the safety and efficacy of Aloxi compared to placebo for the prevention of post-operative nausea and vomiting following elective
The FDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Cefzil tablets of Bristol-Myers Squibb.
This phase Ib trial is designed to evaluate the tolerability, pharmacology and antiviral activity of PRO 140 in patients infected with HIV. PRO 140 binds CCR5, a principal
Spectrum filed a demand for arbitration and statement of claims with the American Arbitration Association. Spectrum said the demand was a response to GPC Biotech excluding Spectrum from
Tekturna was submitted for approval earlier in 2006 to become the first in a new class of high blood pressure medicines for more than a decade. The decision
As part of the agreement Schering-Plough will be responsible for all forward research and development activities, including clinical studies and regulatory filings, continuing its focus on developing hepatitis
Under the agreement, Trana will screen Southern Research’s extensive collection of nucleosides to identify anti-infectives.Trana’s screening assays identify compounds that interrupt the lifecycle of pathogens through a new